Paradigm Biopharmaceuticals Ltd PAR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.27
- Day Range
- A$0.25–0.29
- 52-Week Range
- A$0.25–1.07
- Bid/Ask
- A$0.26 / A$0.27
- Market Cap
- A$89.49 Mil
- Volume/Avg
- 1.5 Mil / 591,967
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,821.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
Comparables
Valuation
|
Metric
|
PAR
|
ICVX
|
SMMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.65 | 3.30 | 32.42 |
Price/Sales | 1,821.43 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PAR
ICVX
SMMT
Financial Strength
|
Metric
|
PAR
|
ICVX
|
SMMT
|
|---|---|---|---|
Quick Ratio | 3.83 | 17.59 | 9.17 |
Current Ratio | 3.83 | 18.06 | 9.30 |
Interest Coverage | −4,970.13 | — | −36.99 |
Quick Ratio
PAR
ICVX
SMMT
Profitability
|
Metric
|
PAR
|
ICVX
|
SMMT
|
|---|---|---|---|
Return on Assets (Normalized) | −101.92% | −29.30% | −25.32% |
Return on Equity (Normalized) | −126.88% | −31.87% | −71.75% |
Return on Invested Capital (Normalized) | −128.45% | −34.69% | −24.62% |
Return on Assets
PAR
ICVX
SMMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jxsdcxqwrc | Ywflc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mpmvjgf | Dvgpjz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rnjstwxbk | Nvpwrm | $97.8 Bil | |
MRNA
| Moderna Inc | Ywwbmnqng | Vlm | $41.3 Bil | |
ARGX
| argenx SE ADR | Jrrgylsd | Bhdq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mshkvmxlh | Hnwk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qysgwczd | Bzwxwxv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qcpqlnnh | Rhnmkl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sldbgjzg | Xtpkrvw | $12.5 Bil | |
INCY
| Incyte Corp | Nmjgctsx | Fcxryh | $11.6 Bil |